Hydroxyalkyl substituted imidazoquinolines
Certain imidazoquinolines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-α biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.
1. A compound of the Formula I:
wherein:
m is 0 or 1;
n is 1 or 2;
R is selected from the group consisting of C 1-10 alkyl, C 1-10 alkoxy, halogen, and C 1-10 haloalkyl;
R 1 is selected from the group consisting of:
—X—Y—R 4 ,
—X—R 5 , and
—X-Het;
X is straight chain or branched chain alkylene optionally interrupted by one —O— group;
Y is selected from the group consisting of —S(O) 0-2 — and —N(R 8 )-Q-;
R 4 is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, and heteroarylalkylenyl, wherein the alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, and heteroarylalkylenyl, groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, amino, alkylamino, dialkylamino, and in the case of alkyl and alkenyl, oxo;
R 5 is selected from the group consisting of:
Het is selected from the group consisting of tetrahydropyranyl and tetrahydrofuranyl;
R 6 is selected from the group consisting of ═O and ═S;
R 7 is C 2-7 alkylene;
R 8 is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, hydroxyalkylenyl, arylalkylenyl, and heteroarylalkylenyl;
R 10 is C 3-8 alkylene;
A is selected from the group consisting of —O—, —C(O)—, —CH 2 —, —S(O) 0-2 —, and —N(Q-R 4 )—;
Q is selected from the group consisting of a bond, —C(R 6 )—, —S(O) 2 , —C(R 6 )—N(R 8 )—, —S(O) 2 —N(R 8 )—, —C(R 6 )—O—, and —C(R 6 )—S—; and
a and b are independently integers from 1 to 6 with the proviso that a+b is <7;
with the proviso that when Y is —S(O) 0-2 — then X can not contain an —O— group;
or a pharmaceutically acceptable salt thereof.
2. The compound or salt of claim 1 , wherein n is 1.
3. The compound or salt of claim 1 , wherein n is 2.
4. The compound or salt of claim 1 , wherein m is 0.
5. The compound or salt of claim 1 , wherein R 1 is —X—Y—R 4 wherein X is straight chain or branched chain C 1-6 alkylene which may be interrupted by one —O— group; Y is selected from the group consisting of —N(R 8 )—C(O)—, —N(R 8 )—S(O) 2 —, —N(R 8 )—C(O)—N(R 8 )—, and
—S(O) 2 — wherein R 8 is selected from hydrogen and methyl; and R 4 is selected from the group consisting of C 1-6 alkyl, isoquinolinyl, N-methylimidazolyl, pyridinyl, quinolinyl, phenyl, and phenyl substituted by a substituent selected from the group consisting of chloro, cyano, fluoro, hydroxy, and methyl.
6. The compound or salt of claim 1 , wherein R 1 is selected from the group consisting of 2-[(cyclopropylcarbonyl)amino]ethyl, 4-[(cyclopropylcarbonyl)amino]butyl, 2-[(cyclohexylcarbonyl)amino]-2-methylpropyl, 2-{[(1-methylethyl)carbonyl]amino}ethyl, 4-{[(1-methylethyl)carbonyl]amino}butyl, 2-methyl-2-{[(1-methylethyl)carbonyl]amino}propyl, 2-[(methylsulfonyl)amino]ethyl, 4-[(methylsulfonyl)amino]butyl, 2-methyl-2-[(methylsulfonyl)amino]propyl, 2-methyl-2-({[(1-methylethyl)amino]carbonyl}amino)propyl, and 2,2-dimethyl-3-(methylsulfonyl)propyl.
7. The compound or salt of claim 1 , wherein R 1 is —X—Y—R 4 wherein X is straight chain or branched chain C 1-8 alkylene which may be interrupted by one —O— group; Y is selected from the group consisting of —N(R 8 )—C(O)—, —N(R 8 )—S(O) 2 —, —N(R 8 )—C(O)—N(R 8a )-, and —S(O) 2 — wherein R 8 is hydrogen, methyl, benzyl, or pyridin-3-ylmethyl; R 8a is hydrogen, methyl, or ethyl, and R 4 is selected from the group consisting of C 1-7 alkyl, haloC 1-4 alkyl, hydroxyC 1-4 alkyl, phenyl, benzyl, 1-phenylethyl, 2-phenylethyl, 2-phenylethenyl, phenylcyclopropyl, pyridinyl, thienyl, N-methylimidazolyl, 3,5-dimethylisoxazolyl, wherein benzyl is unsubstituted or substituted by a methyl group, and phenyl is unsubstituted or substituted by one or two substituents independently selected from the group consisting of methyl, fluoro, chloro, cyano, hydroxy, and dimethylamino.
8. The compound or salt of claim 1 , wherein R 1 is —X—R 5 wherein X is C 1-6 alkylene, and R 5 is
9. The compound or salt of claim 1 , wherein R 1 is selected from the group consisting of 4-(1,1-dioxidoisothiazolidin-2-yl)butyl, 4-[(4-morpholinecarbonyl)amino]butyl, and 2-[(4-morpholinecarbonyl)amino]ethyl.
10. The compound or salt of claim 1 , wherein R 1 is —C 1-4 alkylenyl-Het.
11. The compound or salt of claim 1 , wherein R 1 is tetrahydro-2H-pyran-4-ylmethyl.
12. The compound of claim 1 , selected from the group consisting of N-[4-(4-amino-2-hydroxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide and N-{4-[4-amino-2-(2-hydroxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]}methanesulfonamide, or a pharmaceutically acceptable salt thereof.
13. The compound of claim 1 , wherein the compound is N-{2-[4-amino-2-(hydroxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide or a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 and a pharmaceutically acceptable carrier.
15. A method of preferentially inducing the biosynthesis of IFN-α in an animal comprising administering an effective amount of a compound or salt of claim 1 to the animal.
16. A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.
17. A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.
18. The method of claim 15 , wherein the compound or salt is administered systemically.